[DOI] [PubMed] [Google Scholar] 66.Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H
Parathyroid hormone (PTH) upregulates CYP27B1 and downregulates CYP24A1 to promote active Vitamin D synthesis, whereas fibroblast growth factor 23 (FGF23) exerts opposing effects [97, 98].Additionally, serum phosphate, calcium levels, and 1,25(OH)D itself participate in feedback regulation, creating a dynamic and complex endocrine network [94]
There are some potential biases in these data that we need to be cautious about, but this gives us some valuable insights about the risk profile of these agents that can inform subsequent studies perhaps even a randomized controlled trial that can tease out the specific mechanisms and provide more conclusive evidence. Reduced risk overall GLP-1 receptor agonists have been approved in the United States to treat diabetes since 2005 and obesity since 2014
Its generally safe and well-tolerated, making it a low-risk intervention for a high-impact issue (sleep)